Evidence map›Paper›PMID 42639177›Full record

ReviewFrontiers in pharmacology2026

Precision treatment and frontier advances of glycyrrhizin preparations in drug-induced liver injury (DILI).

Dianya Qiu, Zixuan Gao, Lu Zhang, Tianyu Ma, Xin Wei, Ziyu Zhang, Weihua Cao, Xinxin Li, Shiyu Wang, Wen Deng and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dianya Qiu *Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Zixuan Gao *Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Lu Zhang *Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Tianyu Ma *Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xin WeiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Ziyu ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Weihua CaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xinxin LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Shiyu WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Wen DengDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yaqin ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Linmei YaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Shuojie WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yuyong JiangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yao XieDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Minghui LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury (DILI) is an important drug-induced disease in clinical practice, with a complex pathogenesis and challenges in diagnosis and treatment. Glycyrrhizin preparations are a class of hepatoprotective agents derived from the traditional Chinese medicinal plant Glycyrrhiza uralensis, and have shown significant efficacy in the treatment of DILI due to their multi-target and multi-pathway pharmacological effects. Currently, they have been recommended as core therapeutic drugs for DILI in multiple domestic and international guidelines. This review delves into the advanced evidence-based medical evidence for the treatment of DILI with glycyrrhizin preparations and their recommended status in various guidelines. It also systematically expounds the precise treatment strategies of glycyrrhizin preparations based on DILI classification, severity, and special populations, and elaborately analyzes their cutting-edge mechanisms of action such as regulation of the gut-liver axis and epigenetic modifications. It discusses the challenges in clinical application, such as adverse reactions and predictive markers of efficacy, and their optimization solutions, and looks forward to future research directions. This article aims to promote the precise application of glycyrrhizin preparations in the treatment of DILI, providing practical diagnostic and therapeutic references for clinicians.

Indexed as

Drug-induced liver injury (DILI)evidence-based medicineglycyrrhizin preparationsgut-liver axisprecision treatment

Identifiers

PMID42639177
PMCPMC13500911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.